Measure for measure - Sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 2, 2007, Pages 72-73

  Rosenson, Robert S ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CANNABINOID RECEPTOR ANTAGONIST; FAT; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; SIMVASTATIN PLUS NIACIN; SUGAR; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SHORT SURVEY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; LIPOPROTEINS; METABOLIC SYNDROME X; NIACIN; RISK FACTORS;

EID: 33846416521     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0392     Document Type: Short Survey

References (10)

1. Rosenson RS (2005) New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. Curr Probl Cardiol 30: 241-279
2. Kathiresan S et al. (2006) Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113: 20-29
3. Otvos JD et al. (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113: 1556-1563
4. McKenney JM et al. (2001) Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 88: 270-274
5. Morgan JM et al. (2003) Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 91: 1432-1436
6. Elam MB et al. (2000) Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284: 1263-1270
7. Grundy SM et al. (2002) Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 162: 1568-1576
8. Canner PL et al. (2006) Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 97: 477-479
9. Zhao XQ et al. (2004) Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 93: 307-312
10. Taylor AJ et al. (2004) Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110: 3512-3517